Clinical trials
Heart Diseases trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Terminated | 5 |
| Recruiting | 5 |
| Active, not recruiting | 4 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Abbott Medical Devices | 3 |
| Boston Scientific Corporation | 3 |
| AstraZeneca | 2 |
| Bayside Health | 2 |
| Cardurion Pharmaceuticals, Inc. | 2 |
| Eidos Therapeutics, a BridgeBio company | 2 |
| Eli Lilly and Company | 2 |
| GlaxoSmithKline | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Amarin Pharma Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Diseases | 39 |
| Cardiovascular Diseases | 22 |
| Heart Failure | 9 |
| Stroke | 7 |
| Coronary Artery Disease | 6 |
| Myocardial Infarction | 5 |
| Acute Coronary Syndrome | 4 |
| Atherosclerosis | 4 |
| Cardiomyopathies | 4 |
| Coronary Disease | 4 |
Trials
Showing 26 to 39 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.